DDInter705 DDInter1435
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Exemestane {u} (Compound) resembles {v} (Compound) Loteprednol
Exemestane {u} (Compound) resembles {v} (Compound) Dydrogesterone
Exemestane {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Conjugated estrogens
Exemestane {u} (Compound) treats {v} (Disease) breast cancer
Exemestane {u} (Compound) binds {v} (Gene) CYP19A1
Exemestane {u} (Compound) upregulates {v} (Gene) GLRX
Exemestane {u} (Compound) downregulates {v} (Gene) IGFBP3
Exemestane {u} (Compound) causes {v} (Side Effect) Visual disturbance
Exemestane {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfinpyrazone
Exemestane {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Exemestane (Compound) resembles Loteprednol (Compound)
Exemestane (Compound) resembles Dydrogesterone (Compound)
Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens
Exemestane (Compound) treats breast cancer (Disease)
Exemestane (Compound) binds CYP19A1 (Gene)
Exemestane (Compound) upregulates GLRX (Gene)
Exemestane (Compound) downregulates IGFBP3 (Gene)
Exemestane (Compound) causes Visual disturbance (Side Effect)
Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Exemestane may lead to a major life threatening interaction when taken with Thalidomide